PURPOSE: Prostate cancer is clinically and molecularly heterogeneous. We determined the prognosis of men with ERG-ETS fusions and SPINK1 over expression. MATERIALS AND METHODS: Men were identified with intermediate or high risk localized prostate cancer treated with radical prostatectomy and no therapy before metastasis. A case-cohort design sampled a cohort (262) enriched with metastasis from the entire cohort and a cohort (213) enriched with metastasis from patients with biochemical recurrence. We analyzed transcriptomic profiles and subtyped tumors as m-ERG+, m-ETS+, m-SPINK1+ or Triple Negative (m-ERG─/m-ETS─/m-SPINK1─), and multivariable logistic regression analyses, Kaplan-Meier and multivariable Cox models were used to evaluate subtypes as predictors of clinical outcomes. RESULTS: Overall 36%, 13%, 11% and 40% of prostate cancer was classified as m-ERG+, m-ETS+, m-SPINK1+ and Triple Negative, respectively. Univariable analysis demonstrated that m-SPINK1+ tumors were more common in African-American men (OR 5, 95% CI 1.6-16) but less commonly associated with positive surgical margins (OR 0.16, 95% CI 0.03-0.69) compared to the m-ERG+ group. Compared to the Triple Negative group, m-SPINK1+ showed similar associations with race and surgical margins in univariable and multivariable analyses across the entire cohort. Survival analyses did not show significant differences among m-ERG+, m-ETS+ and Triple Negative cases. m-SPINK1+ independently predicted prostate cancer specific mortality after metastasis (HR 2.48, 95% CI 0.96-6.4) and biochemical recurrence (HR 3, 95% CI 1.1-8). CONCLUSIONS: SPINK1 over expression is associated with prostate cancer specific mortality in at risk men with biochemical and clinical recurrence after prostatectomy. ERG-ETS alterations are not prognostic for outcome.
PURPOSE:Prostate cancer is clinically and molecularly heterogeneous. We determined the prognosis of men with ERG-ETS fusions and SPINK1 over expression. MATERIALS AND METHODS:Men were identified with intermediate or high risk localized prostate cancer treated with radical prostatectomy and no therapy before metastasis. A case-cohort design sampled a cohort (262) enriched with metastasis from the entire cohort and a cohort (213) enriched with metastasis from patients with biochemical recurrence. We analyzed transcriptomic profiles and subtyped tumors as m-ERG+, m-ETS+, m-SPINK1+ or Triple Negative (m-ERG─/m-ETS─/m-SPINK1─), and multivariable logistic regression analyses, Kaplan-Meier and multivariable Cox models were used to evaluate subtypes as predictors of clinical outcomes. RESULTS: Overall 36%, 13%, 11% and 40% of prostate cancer was classified as m-ERG+, m-ETS+, m-SPINK1+ and Triple Negative, respectively. Univariable analysis demonstrated that m-SPINK1+ tumors were more common in African-American men (OR 5, 95% CI 1.6-16) but less commonly associated with positive surgical margins (OR 0.16, 95% CI 0.03-0.69) compared to the m-ERG+ group. Compared to the Triple Negative group, m-SPINK1+ showed similar associations with race and surgical margins in univariable and multivariable analyses across the entire cohort. Survival analyses did not show significant differences among m-ERG+, m-ETS+ and Triple Negative cases. m-SPINK1+ independently predicted prostate cancer specific mortality after metastasis (HR 2.48, 95% CI 0.96-6.4) and biochemical recurrence (HR 3, 95% CI 1.1-8). CONCLUSIONS:SPINK1 over expression is associated with prostate cancer specific mortality in at risk men with biochemical and clinical recurrence after prostatectomy. ERG-ETS alterations are not prognostic for outcome.
Authors: Kathryn L Penney; Jennifer A Sinnott; Katja Fall; Yudi Pawitan; Yujin Hoshida; Peter Kraft; Jennifer R Stark; Michelangelo Fiorentino; Sven Perner; Stephen Finn; Stefano Calza; Richard Flavin; Matthew L Freedman; Sunita Setlur; Howard D Sesso; Swen-Olof Andersson; Neil Martin; Philip W Kantoff; Jan-Erik Johansson; Hans-Olov Adami; Mark A Rubin; Massimo Loda; Todd R Golub; Ove Andrén; Meir J Stampfer; Lorelei A Mucci Journal: J Clin Oncol Date: 2011-05-02 Impact factor: 44.544
Authors: R Jeffrey Karnes; Eric J Bergstralh; Elai Davicioni; Mercedeh Ghadessi; Christine Buerki; Anirban P Mitra; Anamaria Crisan; Nicholas Erho; Ismael A Vergara; Lucia L Lam; Rachel Carlson; Darby J S Thompson; Zaid Haddad; Benedikt Zimmermann; Thomas Sierocinski; Timothy J Triche; Thomas Kollmeyer; Karla V Ballman; Peter C Black; George G Klee; Robert B Jenkins Journal: J Urol Date: 2013-06-11 Impact factor: 7.450
Authors: Stephen R Piccolo; Ying Sun; Joshua D Campbell; Marc E Lenburg; Andrea H Bild; W Evan Johnson Journal: Genomics Date: 2012-08-19 Impact factor: 5.736
Authors: Scott A Tomlins; Daniel R Rhodes; Jianjun Yu; Sooryanarayana Varambally; Rohit Mehra; Sven Perner; Francesca Demichelis; Beth E Helgeson; Bharathi Laxman; David S Morris; Qi Cao; Xuhong Cao; Ove Andrén; Katja Fall; Laura Johnson; John T Wei; Rajal B Shah; Hikmat Al-Ahmadie; James A Eastham; Scott E Eggener; Samson W Fine; Kristina Hotakainen; Ulf-Håkan Stenman; Alex Tsodikov; William L Gerald; Hans Lilja; Victor E Reuter; Phillip W Kantoff; Peter T Scardino; Mark A Rubin; Anders S Bjartell; Arul M Chinnaiyan Journal: Cancer Cell Date: 2008-06 Impact factor: 31.743
Authors: Maria A Svensson; Christopher J LaFargue; Theresa Y MacDonald; Dorothee Pflueger; Naoki Kitabayashi; Ashley M Santa-Cruz; Karl E Garsha; Ubaradka G Sathyanarayana; Janice P Riley; Chol S Yun; Dea Nagy; Jerry W Kosmeder; Gary A Pestano; Ashutosh K Tewari; Francesca Demichelis; Mark A Rubin Journal: Lab Invest Date: 2010-10-25 Impact factor: 5.662
Authors: Walter Rayford; Alp Tuna Beksac; Jordan Alger; Mohammed Alshalalfa; Mohsen Ahmed; Irtaza Khan; Ugo G Falagario; Yang Liu; Elai Davicioni; Daniel E Spratt; Edward M Schaeffer; Felix Y Feng; Brandon Mahal; Paul L Nguyen; Robert B Den; Mark D Greenberger; Randy Bradley; Justin M Watson; Matthew Beamer; Lambros Stamatakis; Darrell J Carmen; Shivanshu Awasthi; Jonathan Hwang; Rachel Weil; Harri Merisaari; Nihal Mohamed; Leslie A Deane; Dimple Chakravarty; Kamlesh K Yadav; Kosj Yamoah; Sujit S Nair; Ashutosh K Tewari Journal: Commun Biol Date: 2021-06-03
Authors: Liana B Guedes; Fawaz Almutairi; Michael C Haffner; Gaurav Rajoria; Zach Liu; Szczepan Klimek; Roberto Zoino; Kasra Yousefi; Rajni Sharma; Angelo M De Marzo; George J Netto; William B Isaacs; Ashley E Ross; Edward M Schaeffer; Tamara L Lotan Journal: Clin Cancer Res Date: 2017-04-26 Impact factor: 12.531
Authors: Alba Torres; Mohammed Alshalalfa; Scott A Tomlins; Nicholas Erho; Ewan A Gibb; Jijumon Chelliserry; Lony Lim; Lucia L C Lam; Sheila F Faraj; Stephania M Bezerra; Elai Davicioni; Kasra Yousefi; Ashley E Ross; George J Netto; Edward M Schaeffer; Tamara L Lotan Journal: J Mol Diagn Date: 2017-03-21 Impact factor: 5.568
Authors: Deli Liu; Michael A Augello; Ivana Grbesa; Davide Prandi; Yang Liu; Jonathan E Shoag; R Jeffrey Karnes; Bruce J Trock; Eric A Klein; Robert B Den; Francesca Demichelis; Elai Davicioni; Andrea Sboner; Christopher E Barbieri Journal: J Clin Invest Date: 2021-05-17 Impact factor: 14.808
Authors: Liana B Guedes; Emmanuel S Antonarakis; Michael T Schweizer; Nooshin Mirkheshti; Fawaz Almutairi; Jong Chul Park; Stephanie Glavaris; Jessica Hicks; Mario A Eisenberger; Angelo M De Marzo; Jonathan I Epstein; William B Isaacs; James R Eshleman; Colin C Pritchard; Tamara L Lotan Journal: Clin Cancer Res Date: 2017-08-08 Impact factor: 12.531
Authors: Alba Torres; Mohammed Alshalalfa; Elai Davicioni; Anuj Gupta; Srinivasan Yegnasubramanian; Sarah J Wheelan; Jonathan I Epstein; Angelo M De Marzo; Tamara L Lotan Journal: Prostate Date: 2018-05-15 Impact factor: 4.104
Authors: Shipra Shukla; Joanna Cyrta; Devan A Murphy; Edward G Walczak; Leili Ran; Praveen Agrawal; Yuanyuan Xie; Yuedan Chen; Shangqian Wang; Yu Zhan; Dan Li; Elissa W P Wong; Andrea Sboner; Himisha Beltran; Juan Miguel Mosquera; Jessica Sher; Zhen Cao; John Wongvipat; Richard P Koche; Anuradha Gopalan; Deyou Zheng; Mark A Rubin; Howard I Scher; Ping Chi; Yu Chen Journal: Cancer Cell Date: 2017-11-16 Impact factor: 31.743
Authors: Alexandra L Tabakin; Evita T Sadimin; Irina Tereshchenko; Aparna Kareddula; Mark N Stein; Tina Mayer; Kim M Hirshfield; Isaac Y Kim; Jay Tischfield; Robert S DiPaola; Eric A Singer Journal: J Genitourin Disord Date: 2018-07-31